Voyager Therapeutics (NASDAQ:VYGR) CEO Alfred Sandrock Sells 12,192 Shares

Voyager Therapeutics, Inc. (NASDAQ:VYGR) CEO Alfred Sandrock sold 12,192 shares of the business’s stock in a transaction that occurred on Tuesday, February 10th. The stock was sold at an average price of $3.78, for a total value of $46,085.76. Following the sale, the chief executive officer owned 509,989 shares of the company’s stock, valued at approximately $1,927,758.42. This trade represents a 2.33% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.

Voyager Therapeutics Stock Performance

Shares of NASDAQ:VYGR traded down $0.05 during trading on Wednesday, reaching $3.65. The stock had a trading volume of 467,225 shares, compared to its average volume of 636,835. Voyager Therapeutics, Inc. has a 1-year low of $2.64 and a 1-year high of $5.55. The stock has a market cap of $202.94 million, a PE ratio of -1.69 and a beta of 1.30. The business has a fifty day moving average price of $4.03 and a 200-day moving average price of $4.09.

Voyager Therapeutics (NASDAQ:VYGR) last announced its quarterly earnings data on Monday, November 10th. The company reported ($0.47) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.06. Voyager Therapeutics had a negative return on equity of 48.94% and a negative net margin of 404.85%.The company had revenue of $11.15 million for the quarter, compared to analyst estimates of $7.86 million. Sell-side analysts expect that Voyager Therapeutics, Inc. will post -0.91 earnings per share for the current year.

Institutional Investors Weigh In On Voyager Therapeutics

A number of institutional investors have recently made changes to their positions in the stock. Ethic Inc. acquired a new position in shares of Voyager Therapeutics in the 2nd quarter worth approximately $123,000. Los Angeles Capital Management LLC purchased a new position in shares of Voyager Therapeutics during the second quarter worth $50,000. Privium Fund Management B.V. grew its stake in shares of Voyager Therapeutics by 16.6% in the second quarter. Privium Fund Management B.V. now owns 25,241 shares of the company’s stock valued at $79,000 after buying an additional 3,596 shares in the last quarter. R Squared Ltd purchased a new stake in shares of Voyager Therapeutics in the 2nd quarter valued at $48,000. Finally, Virtu Financial LLC acquired a new position in Voyager Therapeutics during the 3rd quarter worth about $93,000. 48.03% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on VYGR shares. HC Wainwright dropped their price target on Voyager Therapeutics from $30.00 to $25.00 and set a “buy” rating for the company in a research report on Wednesday, November 12th. Wedbush restated an “outperform” rating and issued a $8.00 target price on shares of Voyager Therapeutics in a report on Tuesday, November 11th. Finally, Wall Street Zen raised Voyager Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, November 15th. Five analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $13.75.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of gene therapies for serious neurological diseases. The company’s core activities center on the design and delivery of engineered adeno-associated viral (AAV) vectors tailored to target cells in the brain and central nervous system. Through its proprietary CapsidMap and VectorMap platforms, Voyager aims to enhance vector potency, specificity and durability to address diseases with high unmet medical need.

The firm’s pipeline includes several AAV-based candidates in preclinical and early clinical development.